Novel therapeutic approaches for multiple myeloma

被引：75

作者：

Hideshima, T ^{[1
]}

Richardson, P ^{[1
]}

Anderson, KC ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA

来源：

IMMUNOLOGICAL REVIEWS | 2003年 / 194卷 / 01期

关键词：

D O I：

10.1034/j.1600-065X.2003.00053.x

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Multiple myeloma (MM) affects 15 000 new patients annually in the US, with 50 000 total patients, and remains incurable. Our preliminary in vitro and animal studies suggest a role for MM-host interactions in regulating MM cell growth, drug resistance, and migration in the bone marrow. Importantly, treatment strategies which target mechanisms whereby MM cells grow and survive in the bone marrow, including thalidomide and its potent immunomodulatory derivatives and proteasome inhibitor PS-341, can overcome classical drug resistance in preclinical and early clinical studies.

引用

页码：164 / 176

页数：13

共 151 条

[1] Role for macrophage inflammatory protein (MIP)-1α and MIP-1β in the development of osteolytic lesions in multiple myeloma [J].

Abe, M ;

Hiura, K ;

Wilde, J ;

Moriyama, K ;

Hashimoto, T ;

Ozaki, S ;

Wakatsuki, S ;

Kosaka, M ;

Kido, S ;

Inoue, D ;

Matsumoto, T .

BLOOD, 2002, 100 (06) :2195-2202

[2]

Adjei AA, 2001, CLIN CANCER RES, V7, P1438

[3]

Akiyama M, 2002, CANCER RES, V62, P3876

[4] Thalidomide for resistant and relapsing myeloma [J].

Alexanian, R ;

Weber, D .

SEMINARS IN HEMATOLOGY, 2000, 37 (01) :22-25

[5] T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect [J].

Alyea, E ;

Weller, E ;

Schlossman, R ;

Canning, C ;

Webb, I ;

Doss, D ;

Mauch, P ;

Marcus, K ;

Fisher, D ;

Freeman, A ;

Parikh, B ;

Gribben, J ;

Soiffer, R ;

Ritz, J ;

Anderson, K .

BLOOD, 2001, 98 (04) :934-939

[6] Targeted therapy for multiple myeloma [J].

Anderson, KC .

SEMINARS IN HEMATOLOGY, 2001, 38 (03) :286-294

[7]

[Anonymous], 1998, J Clin Oncol, V16, P3832

[8]

Attal M, 2002, BLOOD, V100, p5A

[9] Randomized trial experience of the Intergroupe Francophone du Myelome [J].

Attal, M ;

Harousseau, JL .

SEMINARS IN HEMATOLOGY, 2001, 38 (03) :226-230

[10] High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions [J].

Badros, A ;

Barlogie, B ;

Morris, C ;

Desikan, R ;

Martin, SR ;

Munshi, N ;

Zangari, M ;

Toor, A ;

Cottler-Fox, M ;

Fassas, A ;

Aniassie, E ;

Schichman, S ;

Tricot, G .

BLOOD, 2001, 97 (09) :2574-2579

← 1 2 3 4 5 6 7 8 9 10 →